Age and comorbidity identified poor prognosis in elderly patients receiving esophageal chemoradiotherapy
Patients aged ≥75 years with CIRS-G ≥7 had median overall survival of 16 months after definitive chemoradiotherapy.
We read the journals so you don't have to.
A free weekly digest of the radiation oncology research that matters.
Free forever. One email a week. Unsubscribe anytime.
Latest
Early response-adapted TNT preserved the rectum in a minority of selected patients
Two-year sustained complete response was 36% after short-course RT and response-adapted FOLFOX4, while near-complete responses frequently regrew.
Proton hemithoracic irradiation achieved major normal-tissue sparing with limited severe pneumonitis
Proton IMPRINT kept contralateral lung mean dose at 0.3 Gy, with grade 3 pneumonitis occurring in 6% of patients.
Third-course reirradiation provided symptom relief in selected patients with progressive DIPG
Across 12 reported patients receiving at least three radiation courses for DIPG, median survival was 27 months with frequent symptomatic benefit.
Proton hypofractionation achieved durable control in heavily reirradiated spine metastases
Proton hypofractionation produced 10% one-year local failure despite extensive prior irradiation, with grade 3 toxicity confined to multiply reirradiated patients.
Berberine increased radiation-induced DNA damage and tumor suppression in HNSCC models
Berberine enhanced radiation response in HNSCC models by increasing DNA damage and apoptosis while suppressing DNA repair and stemness pathways.
Sexual inactivity and dyspareunia remained common after cervical radio(chemo)therapy
Sexual inactivity reached 49% and dyspareunia 54% after cervical radio(chemo)therapy, with fatigue central to broader survivorship impairment.
HyperSight CBCT approached simulation-CT dosimetry for offline adaptive breast radiotherapy
HyperSight reduced PTV dose-recalculation deviations versus Halcyon 3.1 while using a lower imaging dose in 12 breast radiotherapy patients.
Single-fraction lung SBRT achieved 100% estimated one-year local control in selected patients
Single-fraction SBRT achieved 100% estimated 12-month local control without grade ≥3 toxicity in a selected 49-patient cohort.
Maskless SGRT improved initial pelvic setup and shortened positioning time
Maskless SGRT reduced initial setup error and cut mean positioning time by about 29% compared with thermoplastic-mask alignment.
TBI conditioning outcomes depend on platform and chemotherapy—not radiation dose alone
This review argues against a universal TBI dose, emphasizing conditioning intensity, chemotherapy backbone, disease biology and patient fitness.
Neoadjuvant chemotherapy shifted HR+/HER2− breast tumors toward higher genomic radioresistance
RSI increased after neoadjuvant chemotherapy in 23 of 30 matched HR+/HER2− tumors, but implications for adjuvant radiation dose remain unproven.
No lung subregion strategy clearly improved radiation pneumonitis prediction
Whole-lung, physical-dose and BED3 models performed similarly externally, with the best complete-model AUC only 0.684 and inadequate calibration.
KRAS mutation did not worsen intracranial control after SRS for NSCLC brain metastases
KRAS-mutant and wild-type NSCLC showed similar intracranial control after SRS, while higher radiation dose predicted better outcomes.
Heterogeneous EclipseRT plus PD-1 therapy was feasible in nine bulky NSCLC patients
EclipseRT plus PD-1 blockade produced five responses among nine bulky NSCLC patients without grade ≥3 treatment-related toxicity.